(Q38077281)

28 August 2017

1 reference

title

Asenapine for the treatment of manic and mixed episodes associated with bipolar I disorder: from clinical research to clinical practice (English)

1 reference

28 August 2017

1 reference

1

Andrea Fagiolini

1 reference

28 August 2017

Rocco N Forgione

2

1 reference

28 August 2017

Benedetto Morana

3

1 reference

28 August 2017

Mauro Maccari

4

1 reference

28 August 2017

Arianna Goracci

5

1 reference

28 August 2017

Letizia Bossini

6

1 reference

28 August 2017

Francesca Pellegrini

7

1 reference

28 August 2017

Alessandro Cuomo

8

1 reference

28 August 2017

Francesco Casamassima

9

1 reference

28 August 2017

language of work or name

English

0 references

publication date

29 January 2013

1 reference

Expert Opinion on Pharmacotherapy

28 August 2017

published in

1 reference

28 August 2017

volume

14

1 reference

28 August 2017

issue

4

1 reference

28 August 2017

page(s)

489-504

1 reference

The long-term natural history of the weekly symptomatic status of bipolar I disorder

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

Prodromal and residual symptoms in bipolar I disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

Longitudinal course of bipolar I disorder: duration of mood episodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

Residual symptoms in bipolar disorder: the effect of the last episode after remission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

Costs of bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

Bipolar disorder and the metabolic syndrome: causal factors, psychiatric outcomes and economic burden

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

Health and economic burden of metabolic comorbidity among individuals with bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

Atypical antipsychotic drugs and the risk of sudden cardiac death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: influence of valproic acid augmentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

Asenapine: a novel psychopharmacologic agent with a unique human receptor signature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

Electrophysiological characterization of the effects of asenapine at 5-HT(1A), 5-HT(2A), alpha(2)-adrenergic and D(2) receptors in the rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

Differential regional and dose-related effects of asenapine on dopamine receptor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

Receptor mechanisms of antipsychotic drug action in bipolar disorder - focus on asenapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

Asenapine induces differential regional effects on serotonin receptor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

Repeated effects of asenapine on adrenergic and cholinergic muscarinic receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

Asenapine versus olanzapine in acute mania: a double-blind extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

Quetiapine or haloperidol as monotherapy for bipolar mania--a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

Obesity as a correlate of outcome in patients with bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

The effects of undertreated chronic medical illnesses in patients with severe mental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

Contributions of 5-HT(2C) receptors to multiple actions of central serotonin systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

Genetic knockout and pharmacological blockade studies of the 5-HT7 receptor suggest therapeutic potential in depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

Asenapine effects in animal models of psychosis and cognitive function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: a mixed treatment comparison of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

Prevalence of obesity and weight change during treatment in patients with bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.765859

10.1517/14656566.2013.765859

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference